Torthaí cuardaigh - Timo D. Müller

Beachtaigh na torthaí
  1. 1
    The molecular pharmacology of glucagon agonists in diabetes and obesity

    The molecular pharmacology of glucagon agonists in diabetes and obesity de réir Aaron Novikoff, Timo D. Müller

    Foilsithe / Cruthaithe 2023
    Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  2. 2
    (Patho)Physiology of Glycosylphosphatidylinositol-Anchored Proteins I: Localization at Plasma Membranes and Extracellular Compartments

    (Patho)Physiology of Glycosylphosphatidylinositol-Anchored Proteins I: Localization at Plasma Membranes and Extracellular Compartments de réir Günter Müller, Timo D. Müller

    Foilsithe / Cruthaithe 2023
    Faigh an téacs iomlán Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  3. 3
    Antagonizing GIPR adds fire to the GLP-1R flame

    Antagonizing GIPR adds fire to the GLP-1R flame de réir Aaron Novikoff, Timo D. Müller

    Foilsithe / Cruthaithe 2024
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  4. 4
    Incretin hormones and type 2 diabetes

    Incretin hormones and type 2 diabetes de réir Michael A. Nauck, Timo D. Müller

    Foilsithe / Cruthaithe 2023
    Faigh an téacs iomlán Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  5. 5
    Therapeutic Potential of Targeting the Ghrelin Pathway

    Therapeutic Potential of Targeting the Ghrelin Pathway de réir Gustav Colldén, Matthias H. Tschöp, Timo D. Müller

    Foilsithe / Cruthaithe 2017
    Faigh an téacs iomlán Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  6. 6
    Ghrelin regulation of glucose metabolism

    Ghrelin regulation of glucose metabolism de réir Anne-Laure Poher, Matthias H. Tschöp, Timo D. Müller

    Foilsithe / Cruthaithe 2018
    Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  7. 7
    Gut hormone polyagonists for the treatment of type 2 diabetes

    Gut hormone polyagonists for the treatment of type 2 diabetes de réir Sara J. Brandt, A. Götz, Matthias H. Tschöp, Timo D. Müller

    Foilsithe / Cruthaithe 2018
    Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  8. 8
    Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes

    Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes de réir Robert M. Gutgesell, Rubén Nogueiras, Matthias H. Tschöp, Timo D. Müller

    Foilsithe / Cruthaithe 2024
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  9. 9
    Anti-obesity drug discovery: advances and challenges

    Anti-obesity drug discovery: advances and challenges de réir Timo D. Müller, Matthias Blüher, Matthias H. Tschöp, Richard D. DiMarchi

    Foilsithe / Cruthaithe 2021
    Faigh an téacs iomlán Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  10. 10
    Ghrelin and its potential in the treatment of eating/wasting disorders and cachexia

    Ghrelin and its potential in the treatment of eating/wasting disorders and cachexia de réir Timo D. Müller, Diego Pérez–Tilve, Jenny Tong, Paul T. Pfluger, Matthias H. Tschöp

    Foilsithe / Cruthaithe 2010
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  11. 11
    Anti-Obesity Therapy: from Rainbow Pills to Polyagonists

    Anti-Obesity Therapy: from Rainbow Pills to Polyagonists de réir Timo D. Müller, Christoffer Clemmensen, Brian Finan, Richard D. DiMarchi, M. Tschöp

    Foilsithe / Cruthaithe 2018
    Faigh an téacs iomlán Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  12. 12
    Glucagon Regulation of Energy Expenditure

    Glucagon Regulation of Energy Expenditure de réir Maximilian Kleinert, Stephan Sachs, Kirk M. Habegger, Susanna M. Hofmann, Timo D. Müller

    Foilsithe / Cruthaithe 2019
    Faigh an téacs iomlán Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  13. 13
    Peptide‐based multi‐agonists: a new paradigm in metabolic pharmacology

    Peptide‐based multi‐agonists: a new paradigm in metabolic pharmacology de réir Sara J. Brandt, Timo D. Müller, Richard D. DiMarchi, M. Tschöp, Kerstin Stemmer

    Foilsithe / Cruthaithe 2018
    Faigh an téacs iomlán Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  14. 14
    Glucagon's Metabolic Action in Health and Disease

    Glucagon's Metabolic Action in Health and Disease de réir Anja Zeigerer, Revathi Sekar, Maximilian Kleinert, Shelly Nason, Kirk M. Habegger, Timo D. Müller

    Foilsithe / Cruthaithe 2021
    Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:
  15. 15
    Gut-Brain Cross-Talk in Metabolic Control

    Gut-Brain Cross-Talk in Metabolic Control de réir Christoffer Clemmensen, Timo D. Müller, Stephen C. Woods, Hans-Rudolf Berthoud, Randy J. Seeley, Matthias H. Tschöp

    Foilsithe / Cruthaithe 2017
    Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  16. 16
    GLP-1/glucagon receptor co-agonism for treatment of obesity

    GLP-1/glucagon receptor co-agonism for treatment of obesity de réir Miguel A. Sánchez-Garrido, Sara J. Brandt, Christoffer Clemmensen, Timo D. Müller, Richard D. DiMarchi, Matthias H. Tschöp

    Foilsithe / Cruthaithe 2017
    Faigh an téacs iomlán Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  17. 17
    GIPR/GLP-1R dual agonist therapies for diabetes and weight loss—chemistry, physiology, and clinical applications

    GIPR/GLP-1R dual agonist therapies for diabetes and weight loss—chemistry, physiology, and clinical applications de réir Jonathan E. Campbell, Timo D. Müller, Brian Finan, Richard D. DiMarchi, Matthias H. Tschöp, David A. D’Alessio

    Foilsithe / Cruthaithe 2023
    Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  18. 18
    Unimolecular Polypharmacy for Treatment of Diabetes and Obesity

    Unimolecular Polypharmacy for Treatment of Diabetes and Obesity de réir Matthias H. Tschöp, Brian Finan, Christoffer Clemmensen, Vasily M. Gelfanov, Diego Pérez–Tilve, Timo D. Müller, Richard D. DiMarchi

    Foilsithe / Cruthaithe 2016
    Faigh an téacs iomlán Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  19. 19
    Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes

    Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes de réir Qiming Tan, Seun Akindehin, Camila E. Orsso, Richelle C. Waldner, Richard D. DiMarchi, Timo D. Müller, Andrea M. Haqq

    Foilsithe / Cruthaithe 2022
    Faigh an téacs iomlán Faigh an téacs iomlán
    Revisão
    Cuir le mo chuid Ceanán
    Sábháilte in:
  20. 20
    'Fat mass and obesity associated' gene (FTO): No significant association of variant rs9939609 with weight loss in a lifestyle intervention and lipid metabolism markers in German obese children and adolescents

    'Fat mass and obesity associated' gene (FTO): No significant association of variant rs9939609 with weight loss in a lifestyle intervention and lipid metabolism markers in German ob... de réir Timo D. Müller, Anke Hinney, André Scherag, Thuy Trang Nguyen, Felix Schreiner, H. Schäfer, Johannes Hebebrand, Christian L. Roth, Thomas Reinehr

    Foilsithe / Cruthaithe 2008
    Faigh an téacs iomlán Faigh an téacs iomlán
    Artigo
    Cuir le mo chuid Ceanán
    Sábháilte in:

Uirlisí cuardaigh: